During the last session, Immix Biopharma Inc (NASDAQ:IMMX)’s traded shares were 0.19 million, with the beta value of the company hitting 0.30. At the end of the trading day, the stock’s price was $2.39, reflecting an intraday gain of 4.82% or $0.11. The 52-week high for the IMMX share is $3.00, that puts it down -25.52 from that peak though still a striking 47.28% gain since the share price plummeted to a 52-week low of $1.26. The company’s market capitalization is $66.63M, and the average trade volume was 203.15K shares over the past three months.
Immix Biopharma Inc (IMMX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. IMMX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.
Immix Biopharma Inc (NASDAQ:IMMX) trade information
Immix Biopharma Inc (IMMX) registered a 4.82% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 4.82% in intraday trading to $2.39, hitting a weekly high. The stock’s 5-day price performance is -1.65%, and it has moved by 13.27% in 30 days. Based on these gigs, the overall price performance for the year is 16.02%.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 65.86% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, IMMX is trading at a discount of -192.89% off the target high and -192.89% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -43.61%. While earnings are projected to return 16.78% in 2025.
IMMX Dividends
Immix Biopharma Inc is due to release its next quarterly earnings on 2025-May-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Immix Biopharma Inc (NASDAQ:IMMX)’s Major holders
Immix Biopharma Inc insiders own 40.89% of total outstanding shares while institutional holders control 12.28%, with the float percentage being 20.77%. AIGH CAPITAL MANAGEMENT LLC is the largest shareholder of the company, while 29.0 institutions own stock in it. As of 2024-06-30, the company held over 1.41 million shares (or 6.0017% of all shares), a total value of $2.79 million in shares.
The next largest institutional holding, with 0.85 million shares, is of BLEICHROEDER LP’s that is approximately 3.6266% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.68 million.
